ClinicalTrials.gg
CompletedNCT01571284Updated Apr 17, 2018Results posted

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

A Phase 3 interventional study of AFLIBERCEPT AVE0005 and FOLFIRI in Colorectal Cancer Metastatic, sponsored by Sanofi. Completed at 179 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
781
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
2nd of 24
781 · median 63
Started
2012
with 6 others
Phase 3
4 of 24
none open now
Registered
4th of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 2nd largest by enrollment, is one of 7 that started in 2012, is one of 4 in phase 3, and was the 4th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants

Secondary Objective:

To document the Health-Related Quality of Life of aflibercept in this participants population

Read the detailed description

Each participants will be treated until disease progression, unacceptable toxicity, death, Investigator's decision or participant's refusal for further treatment (whichever comes first). Participants were followed-up during study treatment and for at least 30 days after last administration.

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically proven adenocarcinoma of the colon or rectum.
  • disease.
  • performance status 0-1.
  • One and only one prior chemotherapeutic regimen for metastatic disease. This prior chemotherapy was an oxaliplatin containing regimen. Participants must had progressed during or after the oxaliplatin based chemotherapy. Participants within 6 months of completion of oxaliplatin chemotherapy were eligible.
  • Signed written obtained prior to inclusion.

Exclusion criteria

Exclusion criteria:

  • Prior therapy with irinotecan.
  • Inadequate bone marrow, liver and renal function: neutrophils \< 1.5x109/L, \< 100x109/L, \< 9.0 g/dL, total >1.5 x upper normal limit (), transaminases >3 x ULN (unless liver are present), alkaline phosphatase >3 x ULN (unless liver metastasis are present), serum creatinine > 1.5 x ULN.
  • Less than 4 weeks from prior radiotherapy, prior chemotherapy, prior major surgery (or until the surgical wound were fully healed).
  • Treatment with any drug within the prior 30 days.
  • Treatment with concomitant anticonvulsivant agents that were inducers (phenytoin, phenobarbital, carbamazepine), unless discontinued >7 days.
  • History of , uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or .
  • Prior (other than colorectal) including prior malignancy from which the participants had been disease free for \< 5 years (except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix).
  • Any of the following within 6 months prior to study inclusion: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, severe congestive heart failure, stroke or .
  • Any of the following within 3 months prior study inclusion: severe gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
  • Occurrence of deep vein thrombosis within 4 weeks, prior to study inclusion.
  • Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known disease requiring antiretroviral treatment.
  • Known dihydropyrimidine dehydrogenase deficiency.
  • Predisposing colonic or small bowel disorders in which the symptoms were uncontrolled.
  • Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, unresolved bowel obstruction/sub-obstruction, more than hemicolectomy, extensive small intestine resection with chronic diarrhea.
  • Known Gilbert's syndrome.
  • Unresolved or unstable toxicity from any prior anti cancer therapy at the time of inclusion.
  • History of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with FOLFIRI (irinotecan, 5-Fluorouracil, leucovorin).
  • Severe acute or chronic medical condition, which could impair the ability of the participants to participate to the study.
  • Urine protein-creatinine ratio (UPCR) >1 on morning spot urinalysis or proteinuria > 500 mg/24-h.
  • Uncontrolled hypertension within 3 months prior to study inclusion.
  • Participants on anticoagulant therapy with unstable dose of warfarin and/or had an out-of-therapeutic range within the 4 weeks prior to study inclusion.
  • Evidence of bleeding predisposition or underlying coagulopathy, non-healing wound.
  • Pregnant or breast-feeding women.
  • Participants with who were not agree to use an accepted effective method of .

The above information wass not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
781 participants (actual)

Study arms

  • Experimental
    Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)

    Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m\^2 IV infusion over 90 minutes and Leucovorin 400 mg/m\^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m\^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m\^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.

    Drug: AFLIBERCEPT AVE0005 · Drug: FOLFIRI

Interventions

  • Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous

  • DrugFOLFIRI

    irinotecan, 5-FU and leucovorin

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  2. Number of Participants With Abnormal Hematological Parameters

    Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  3. Number of Participants With International Normalized Ratio (INR)

    The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  4. Number of Participants With Abnormal Electrolytes Parameters

    Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  5. Number of Participants With Abnormal Renal and Liver Function Parameters

    Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  6. Creatinine Clearance of Aflibercept Plus FOLFIRI

    Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD).

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  7. Number of Participants With Other Abnormal Biochemistry Parameters

    Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  8. Number of Participants With Abnormal Non-Gradable Biochemistry Parameters

    Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with \<lower limit of normal ranges (LLN) and \>upper limit of normal ranges (ULN) for each of these parameters were reported.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  9. Number of Participants With Proteinuria Events

    Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  10. Number of Participants With Proteinuria Grade >=2

    Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  11. Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)

    Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is \< or = 1.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  12. Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension

    Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

  13. Number of Participants With Cycle Delay and/or Dose Modification

    A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission.

    Time frame: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

Secondary outcomes

  1. Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)

  2. Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

  3. Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales

    EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

  4. Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score

    EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

  5. Change From Baseline in HRQL EQ-5D-3L VAS Score

    EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.

    Time frame: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

07

Results

Posted Feb 27, 2018

Participant flow

The study was conducted at 151 sites in 23 countries. A total of 798 participants were screened between 30 May 2012 and 03 January 2015, out of which 781 participants were enrolled and 779 participants were treated.

Participant flow — Overall Study
MilestoneAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Started781
Safety population779
Completed612
Not completed169
Withdrew: Participant's decision84
Withdrew: Lost to follow-up3
Withdrew: Enrolled but not treated2
Withdrew: Other than specified above80

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Any TEAE (All Grades)769
Any TEAEs (Grades 3-4)609
Any serious TEAE272
Any serious related TEAE159
Any TEAE leading to death47
Any TEAE (permanent treatment discontinuation)208
Any TEAE (premature treatment discontinuation)104
PrimaryNumber of Participants With Abnormal Hematological Parameters

Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematological Parameters
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Anaemia: All Grades535
Anaemia: Grades 3-414
Thrombocytopenia: All Grades293
Thrombocytopenia: Grades 3-413
Leukopenia: All Grades532
Leukopenia: Grades 3-472
Neutropenia: All Grades450
Neutropenia: Grades 3-4227
PrimaryNumber of Participants With International Normalized Ratio (INR)

The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With International Normalized Ratio (INR)
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
INR<1.5106
INR>=1.5 to <30
INR>=3 to <52
INR>=52
PrimaryNumber of Participants With Abnormal Electrolytes Parameters

Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrolytes Parameters
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Hyponatremia: All Grades181
Hyponatremia: Grades 3-432
Hypernatremia: All Grades75
Hypernatremia: Grades 3-41
Hypocalcemia: All Grades213
Hypocalcemia: Grades 3-45
Hypercalcemia: All Grades52
Hypercalcemia: Grades 3-42
Hypokalemia: All Grades121
Hypokalemia: Grades 3-416
Hyperkalemia: All Grades166
Hyperkalemia: Grades 3-410
PrimaryNumber of Participants With Abnormal Renal and Liver Function Parameters

Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Renal and Liver Function Parameters
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Creatinine: All Grades161
Creatinine: Grades 3-42
Hyperbilirubinemia: All Grades130
Hyperbilirubinemia: Grades 3-49
AST: All Grades342
AST: Grades 3-412
ALT: All Grades270
ALT: Grades 3-410
Alkaline phosphatase: All Grades465
Alkaline phosphatase: Grades 3-423
PrimaryCreatinine Clearance of Aflibercept Plus FOLFIRI

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD).

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Mean · mL/min
Creatinine Clearance of Aflibercept Plus FOLFIRI
mL/minAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Creatinine Clearance of Aflibercept Plus FOLFIRI71.4 ± 29.3
PrimaryNumber of Participants With Other Abnormal Biochemistry Parameters

Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Other Abnormal Biochemistry Parameters
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Hypoglycemia: All Grades90
Hypoglycemia: Grades 3-46
Hyperglycemia: All Grades403
Hyperglycemia: Grades 3-430
Hypoalbuminemia: All Grades241
Hypoalbuminemia: Grades 3-46
PrimaryNumber of Participants With Abnormal Non-Gradable Biochemistry Parameters

Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with \<lower limit of normal ranges (LLN) and \>upper limit of normal ranges (ULN) for each of these parameters were reported.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Non-Gradable Biochemistry Parameters
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Chloride<LLN135
Chloride>ULN217
BUN<LLN41
BUN>ULN83
UREA<LLN60
UREA>ULN250
LDH<LLN79
LDH>ULN423
Total proteins<LLN162
Total proteins>ULN77
PrimaryNumber of Participants With Proteinuria Events

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Proteinuria Events
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Grade 1286
Grade 2123
Grade 354
Grade 45
PrimaryNumber of Participants With Proteinuria Grade >=2

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Number · participants
Number of Participants With Proteinuria Grade >=2
participantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Number of Participants With Proteinuria Grade >=2182
PrimaryNumber of Participants With Urinary Protein-Creatinine Ratio (UPCR)

Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is \< or = 1.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
UPCR<=1265
UPCR>=1 to <=251
UPCR>=2 to <=324
UPCR>327
PrimaryNumber of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension

Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade \>=2 (graded as per NCI CTCAE Version 4.03), where Grade\>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Proteinuria with hematuria72
Proteinuria with hypertension4
Proteinuria with hematuria and hypertension3
PrimaryNumber of Participants With Cycle Delay and/or Dose Modification

A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission.

Time frame:
Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Cycle Delay and/or Dose Modification
ParticipantsAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
No delay and no dose modification119
Any delay and/or dose modification660
Delay only163
Delay and Aflibercept modified39
Delay and FOLFIRI modified308
Delay and Aflibercept and Folfiri modified97
Only Aflibercept modified5
Only FOLFIRI modified43
Both Aflibercept and FOLFIRI modified5
SecondaryMean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
Reported as:
Mean · units on a scale
Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline68.61 ± 20.48
Change at Cycle 3-3.34 ± 18.83
Change at Cycle 5-4.70 ± 18.89
Change at Cycle 7-3.63 ± 22.02
Change at Cycle 9-3.97 ± 21.31
Change at Cycle 11-5.85 ± 22.26
Change at Cycle 13-2.26 ± 21.69
Change at Cycle 15-3.05 ± 22.46
Change at Cycle 17-1.18 ± 22.50
Change at Cycle 19-2.36 ± 22.92
Change at Cycle 21-5.56 ± 23.77
Change at Cycle 23-6.86 ± 19.94
Change at Cycle 25-8.05 ± 16.89
Change at Cycle 27-10.14 ± 17.58
Change at Cycle 29-8.33 ± 14.05
Change at Cycle 31-9.44 ± 16.92
Change at Cycle 33-11.36 ± 21.82
Change at Cycle 35-5.83 ± 20.81
Change at EOT-8.82 ± 23.95
SecondaryMean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Reported as:
Mean · units on a scale
Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Physical - Baseline81.79 ± 19.41
Physical - Change at Cycle 3-3.73 ± 15.15
Physical - Change at Cycle 5-3.95 ± 15.22
Physical - Change at Cycle 7-4.62 ± 16.23
Physical - Change at Cycle 9-4.36 ± 15.79
Physical - Change at Cycle 11-6.99 ± 17.89
Physical - Change at Cycle 13-4.99 ± 16.17
Physical - Change at Cycle 15-3.54 ± 15.99
Physical - Change at Cycle 17-5.10 ± 16.20
Physical - Change at Cycle 19-5.68 ± 16.23
Physical - Change at Cycle 21-5.70 ± 13.01
Physical - Change at Cycle 23-7.87 ± 14.38
Physical - Change at Cycle 25-5.75 ± 12.18
Physical - Change at Cycle 27-6.59 ± 11.64
Physical - Change at Cycle 29-7.67 ± 11.09
Physical - Change at Cycle 31-9.33 ± 14.65
Physical - Change at Cycle 33-5.45 ± 9.81
Physical - Change at Cycle 35-10.00 ± 13.05
Physical - Change at EOT-11.16 ± 21.65
Role - Baseline79.91 ± 26.25
Role - Change at Cycle 3-6.26 ± 25.22
Role - Change at Cycle 5-5.66 ± 23.26
Role - Change at Cycle 7-6.68 ± 24.29
Role - Change at Cycle 9-6.55 ± 23.95
Role - Change at Cycle 11-8.76 ± 26.35
Role - Change at Cycle 13-7.36 ± 23.41
Role - Change at Cycle 15-7.18 ± 21.98
Role - Change at Cycle 17-9.58 ± 22.54
Role - Change at Cycle 19-9.84 ± 22.44
Role - Change at Cycle 21-9.78 ± 18.11
Role - Change at Cycle 23-10.65 ± 18.32
Role - Change at Cycle 25-10.92 ± 17.97
Role - Change at Cycle 27-10.14 ± 17.22
Role - Change at Cycle 29-10.83 ± 17.33
Role - Change at Cycle 31-14.44 ± 18.76
Role - Change at Cycle 33-15.15 ± 15.73
Role - Change at Cycle 35-15.00 ± 16.57
Role - Change at EOT-12.11 ± 28.22
Emotional - Baseline78.96 ± 20.60
Emotional - Change at Cycle 31.14 ± 19.95
Emotional - Change at Cycle 50.74 ± 19.32
Emotional - Change at Cycle 71.58 ± 20.91
Emotional - Change at Cycle 91.69 ± 21.38
Emotional - Change at Cycle 110.08 ± 20.40
Emotional - Change at Cycle 130.93 ± 20.08
Emotional - Change at Cycle 152.51 ± 20.23
Emotional - Change at Cycle 172.91 ± 18.23
Emotional - Change at Cycle 191.39 ± 17.60
Emotional - Change at Cycle 210.06 ± 17.86
Emotional - Change at Cycle 231.75 ± 19.29
Emotional - Change at Cycle 254.98 ± 15.86
Emotional - Change at Cycle 271.57 ± 17.64
Emotional - Change at Cycle 292.64 ± 17.88
Emotional - Change at Cycle 311.30 ± 17.78
Emotional - Change at Cycle 330.25 ± 3.82
Emotional - Change at Cycle 35-0.00 ± 5.56
Emotional - Change at EOT-2.87 ± 22.52
Cognitive - Baseline86.90 ± 19.26
Cognitive - Change at Cycle 3-1.77 ± 16.92
Cognitive - Change at Cycle 5-1.87 ± 16.58
Cognitive - Change at Cycle 7-1.99 ± 19.71
Cognitive - Change at Cycle 9-2.18 ± 20.17
Cognitive - Change at Cycle 11-4.27 ± 20.29
Cognitive - Change at Cycle 13-2.83 ± 17.40
Cognitive - Change at Cycle 15-2.28 ± 19.40
Cognitive - Change at Cycle 17-3.45 ± 19.38
Cognitive - Change at Cycle 19-5.00 ± 22.19
Cognitive - Change at Cycle 21-5.56 ± 16.28
Cognitive - Change at Cycle 23-5.71 ± 14.54
Cognitive - Change at Cycle 25-6.90 ± 21.14
Cognitive - Change at Cycle 27-5.80 ± 16.37
Cognitive - Change at Cycle 29-6.67 ± 18.26
Cognitive - Change at Cycle 31-5.56 ± 15.00
Cognitive - Change at Cycle 33-10.61 ± 17.12
Cognitive - Change at Cycle 35-11.67 ± 13.72
Cognitive- Change at EOT-4.98 ± 22.67
Social - Baseline80.57 ± 24.68
Social - Change at Cycle 3-2.05 ± 22.83
Social - Change at Cycle 5-2.86 ± 21.60
Social - Change at Cycle 7-4.78 ± 23.65
Social - Change at Cycle 9-4.56 ± 23.84
Social - Change at Cycle 11-7.09 ± 24.83
Social - Change at Cycle 13-5.56 ± 24.03
Social - Change at Cycle 15-6.18 ± 23.23
Social - Change at Cycle 17-5.56 ± 22.69
Social - Change at Cycle 19-5.28 ± 22.02
Social - Change at Cycle 21-5.56 ± 21.61
Social - Change at Cycle 23-7.62 ± 17.78
Social - Change at Cycle 25-4.60 ± 18.31
Social - Change at Cycle 27-2.17 ± 17.63
Social - Change at Cycle 29-5.00 ± 18.81
Social - Change at Cycle 31-7.78 ± 25.09
Social - Change at Cycle 33-1.52 ± 17.41
Social - Change at Cycle 35-1.67 ± 14.59
Social - Change at EOT-9.01 ± 26.23
SecondaryChange From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) \& other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health \& quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 \& 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Fatigue - Baseline29.16 ± 23.48
Fatigue - Change at Cycle 37.35 ± 21.62
Fatigue - Change at Cycle 58.40 ± 21.88
Fatigue - Change at Cycle 79.54 ± 22.60
Fatigue - Change at Cycle 97.89 ± 21.80
Fatigue - Change at Cycle 1111.30 ± 23.73
Fatigue - Change at Cycle 138.33 ± 21.72
Fatigue - Change at Cycle 157.41 ± 22.38
Fatigue - Change at Cycle 176.70 ± 21.25
Fatigue - Change at Cycle 198.93 ± 19.83
Fatigue - Change at Cycle 2110.39 ± 17.90
Fatigue - Change at Cycle 2310.80 ± 18.49
Fatigue - Change at Cycle 257.66 ± 19.94
Fatigue - Change at Cycle 279.66 ± 18.74
Fatigue - Change at Cycle 2911.67 ± 18.55
Fatigue - Change at Cycle 3114.07 ± 21.61
Fatigue - Change at Cycle 3315.15 ± 21.81
Fatigue - Change at Cycle 3514.44 ± 18.92
Fatigue - Change at EOT12.31 ± 25.56
Nausea and Vomiting - Baseline5.88 ± 13.99
Nausea and Vomiting - Change at Cycle 36.68 ± 19.81
Nausea and Vomiting - Change at Cycle 56.98 ± 19.79
Nausea and Vomiting - Change at Cycle 76.61 ± 18.07
Nausea and Vomiting - Change at Cycle 96.20 ± 19.68
Nausea and Vomiting - Change at Cycle 118.97 ± 19.83
Nausea and Vomiting - Change at Cycle 136.82 ± 14.71
Nausea and Vomiting - Change at Cycle 156.85 ± 16.33
Nausea and Vomiting - Change at Cycle 173.45 ± 15.49
Nausea and Vomiting - Change at Cycle 196.56 ± 14.04
Nausea and Vomiting - Change at Cycle 213.99 ± 14.14
Nausea and Vomiting - Change at Cycle 237.87 ± 10.90
Nausea and Vomiting - Change at Cycle 254.02 ± 8.52
Nausea and Vomiting - Change at Cycle 277.25 ± 11.04
Nausea and Vomiting - Change at Cycle 291.67 ± 5.13
Nausea and Vomiting - Change at Cycle 3113.33 ± 28.31
Nausea and Vomiting - Change at Cycle 333.03 ± 6.74
Nausea and Vomiting - Change at Cycle 353.33 ± 7.03
Nausea and Vomiting - Change at EOT6.64 ± 21.11
Pain - Baseline20.47 ± 25.08
Pain - Change at Cycle 32.68 ± 25.02
Pain - Change at Cycle 52.52 ± 23.48
Pain - Change at Cycle 73.00 ± 24.98
Pain - Change at Cycle 92.72 ± 24.45
Pain - Change at Cycle 116.64 ± 23.68
Pain - Change at Cycle 135.16 ± 19.79
Pain - Change at Cycle 157.26 ± 21.91
Pain - Change at Cycle 179.39 ± 22.97
Pain - Change at Cycle 198.74 ± 22.28
Pain - Change at Cycle 217.25 ± 18.14
Pain - Change at Cycle 238.33 ± 19.31
Pain - Change at Cycle 255.75 ± 21.02
Pain - Change at Cycle 275.07 ± 17.72
Pain - Change at Cycle 294.17 ± 16.11
Pain - Change at Cycle 3110.00 ± 23.40
Pain - Change at Cycle 337.58 ± 22.81
Pain - Change at Cycle 356.67 ± 21.08
Pain - Change at EOT10.85 ± 28.99
Dyspnoea - Baseline13.45 ± 22.01
Dyspnoea - Change at Cycle 33.63 ± 22.96
Dyspnoea - Change at Cycle 55.75 ± 24.06
Dyspnoea - Change at Cycle 76.98 ± 24.47
Dyspnoea - Change at Cycle 96.89 ± 24.38
Dyspnoea - Change at Cycle 118.19 ± 26.59
Dyspnoea - Change at Cycle 136.36 ± 25.37
Dyspnoea - Change at Cycle 153.58 ± 24.65
Dyspnoea - Change at Cycle 175.16 ± 24.54
Dyspnoea - Change at Cycle 196.78 ± 26.82
Dyspnoea - Change at Cycle 213.79 ± 22.98
Dyspnoea - Change at Cycle 234.04 ± 20.00
Dyspnoea - Change at Cycle 251.23 ± 21.64
Dyspnoea - Change at Cycle 273.03 ± 22.79
Dyspnoea - Change at Cycle 29-1.75 ± 23.50
Dyspnoea - Change at Cycle 3116.67 ± 28.50
Dyspnoea - Change at Cycle 3316.67 ± 17.57
Dyspnoea - Change at Cycle 3516.67 ± 23.57
Dyspnoea - Change at EOT6.53 ± 25.79
Insomnia - Baseline24.15 ± 28.09
Insomnia - Change at Cycle 30.37 ± 27.36
Insomnia - Change at Cycle 5-0.08 ± 28.48
Insomnia - Change at Cycle 7-2.37 ± 29.63
Insomnia - Change at Cycle 9-0.24 ± 29.37
Insomnia - Change at Cycle 112.56 ± 28.86
Insomnia - Change at Cycle 130.65 ± 26.89
Insomnia - Change at Cycle 15-2.19 ± 27.01
Insomnia - Change at Cycle 17-1.92 ± 25.60
Insomnia - Change at Cycle 191.64 ± 23.12
Insomnia - Change at Cycle 210.74 ± 25.11
Insomnia - Change at Cycle 23-0.93 ± 33.32
Insomnia - Change at Cycle 25-0.00 ± 28.17
Insomnia - Change at Cycle 27-1.52 ± 24.07
Insomnia - Change at Cycle 29-3.33 ± 30.40
Insomnia - Change at Cycle 31-4.44 ± 41.53
Insomnia - Change at Cycle 33-6.06 ± 32.72
Insomnia - Change at Cycle 35-3.33 ± 33.15
Insomnia - Change at EOT5.31 ± 32.50
Appetite loss - Baseline17.38 ± 26.01
Appetite loss - Change at Cycle 39.10 ± 28.64
Appetite loss - Change at Cycle 59.02 ± 28.14
Appetite loss - Change at Cycle 79.84 ± 27.80
Appetite loss - Change at Cycle 99.98 ± 27.18
Appetite loss - Change at Cycle 1114.53 ± 28.27
Appetite loss - Change at Cycle 1310.67 ± 27.12
Appetite loss - Change at Cycle 1510.74 ± 25.90
Appetite loss - Change at Cycle 178.91 ± 24.75
Appetite loss - Change at Cycle 199.84 ± 24.60
Appetite loss - Change at Cycle 2113.04 ± 25.80
Appetite loss - Change at Cycle 2312.38 ± 25.67
Appetite loss - Change at Cycle 2511.49 ± 20.46
Appetite loss - Change at Cycle 2715.94 ± 22.18
Appetite loss - Change at Cycle 2915.00 ± 20.16
Appetite loss - Change at Cycle 3115.56 ± 24.77
Appetite loss - Change at Cycle 3315.15 ± 22.92
Appetite loss - Change at Cycle 3516.67 ± 17.57
Appetite loss - Change at EOT12.03 ± 33.48
Constipation - Baseline12.71 ± 21.61
Constipation - Change at Cycle 32.42 ± 25.25
Constipation - Change at Cycle 53.77 ± 26.52
Constipation - Change at Cycle 72.63 ± 26.09
Constipation - Change at Cycle 95.35 ± 26.68
Constipation - Change at Cycle 114.42 ± 26.47
Constipation - Change at Cycle 134.58 ± 25.95
Constipation - Change at Cycle 154.92 ± 26.30
Constipation - Change at Cycle 175.43 ± 23.35
Constipation - Change at Cycle 198.33 ± 21.81
Constipation - Change at Cycle 216.06 ± 18.00
Constipation - Change at Cycle 239.26 ± 21.98
Constipation - Change at Cycle 255.75 ± 17.97
Constipation - Change at Cycle 271.45 ± 12.22
Constipation - Change at Cycle 296.67 ± 20.52
Constipation - Change at Cycle 3122.22 ± 32.53
Constipation - Change at Cycle 3312.12 ± 16.82
Constipation - Change at Cycle 3510.00 ± 16.10
Constipation - Change at EOT3.78 ± 27.33
Diarrhoea - Baseline10.37 ± 19.47
Diarrhoea - Change at Cycle 311.72 ± 28.16
Diarrhoea - Change at Cycle 510.85 ± 28.29
Diarrhoea - Change at Cycle 714.63 ± 29.94
Diarrhoea - Change at Cycle 911.44 ± 26.44
Diarrhoea - Change at Cycle 1115.46 ± 27.26
Diarrhoea - Change at Cycle 1311.26 ± 24.00
Diarrhoea - Change at Cycle 1511.02 ± 28.02
Diarrhoea - Change at Cycle 1710.34 ± 21.75
Diarrhoea - Change at Cycle 1915.25 ± 25.76
Diarrhoea - Change at Cycle 2114.07 ± 24.09
Diarrhoea - Change at Cycle 2318.52 ± 21.74
Diarrhoea - Change at Cycle 2510.34 ± 22.01
Diarrhoea - Change at Cycle 2713.64 ± 19.68
Diarrhoea - Change at Cycle 2916.67 ± 25.36
Diarrhoea - Change at Cycle 3120.00 ± 24.56
Diarrhoea - Change at Cycle 3318.18 ± 22.92
Diarrhoea - Change at Cycle 3530.00 ± 18.92
Diarrhoea - Change at EOT7.31 ± 24.26
Financial difficulties - Baseline20.12 ± 30.25
Financial difficulties - Change at Cycle 3-1.83 ± 23.80
Financial difficulties - Change at Cycle 5-1.32 ± 24.00
Financial difficulties - Change at Cycle 7-0.99 ± 27.68
Financial difficulties - Change at Cycle 9-0.49 ± 26.80
Financial difficulties - Change at Cycle 113.30 ± 25.64
Financial difficulties - Change at Cycle 131.11 ± 27.96
Financial difficulties - Change at Cycle 15-0.27 ± 27.94
Financial difficulties - Change at Cycle 170.77 ± 27.36
Financial difficulties - Change at Cycle 191.67 ± 29.70
Financial difficulties - Change at Cycle 214.44 ± 25.23
Financial difficulties - Change at Cycle 232.94 ± 23.74
Financial difficulties - Change at Cycle 25-4.60 ± 19.36
Financial difficulties - Change at Cycle 27-2.90 ± 24.44
Financial difficulties - Change at Cycle 290.00 ± 21.63
Financial difficulties - Change at Cycle 31-2.22 ± 19.79
Financial difficulties - Change at Cycle 33-3.03 ± 17.98
Financial difficulties - Change at Cycle 350.00 ± 15.71
Financial difficulties - Change at EOT2.97 ± 27.90
SecondaryChange From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline0.77 ± 0.24
Change at Cycle 3-0.02 ± 0.23
Change at Cycle 5-0.03 ± 0.22
Change at Cycle 7-0.04 ± 0.23
Change at Cycle 9-0.05 ± 0.24
Change at Cycle 11-0.07 ± 0.25
Change at Cycle 13-0.05 ± 0.20
Change at Cycle 15-0.06 ± 0.23
Change at Cycle 17-0.05 ± 0.24
Change at Cycle 19-0.05 ± 0.18
Change at Cycle 21-0.09 ± 0.20
Change at Cycle 23-0.14 ± 0.26
Change at Cycle 25-0.08 ± 0.21
Change at Cycle 27-0.08 ± 0.21
Change at Cycle 29-0.08 ± 0.20
Change at Cycle 31-0.12 ± 0.30
Change at Cycle 330.02 ± 0.14
Change at Cycle 35-0.05 ± 0.14
Change at EOT-0.11 ± 0.30
SecondaryChange From Baseline in HRQL EQ-5D-3L VAS Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems \& severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.

Time frame:
Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in HRQL EQ-5D-3L VAS Score
units on a scaleAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Baseline72.81 ± 18.28
Change at Cycle 3-1.85 ± 15.35
Change at Cycle 5-2.15 ± 14.31
Change at Cycle 7-2.20 ± 16.33
Change at Cycle 9-2.74 ± 14.28
Change at Cycle 11-3.10 ± 14.40
Change at Cycle 13-2.36 ± 15.29
Change at Cycle 15-1.05 ± 15.51
Change at Cycle 17-1.91 ± 13.54
Change at Cycle 19-3.06 ± 13.85
Change at Cycle 21-2.13 ± 14.98
Change at Cycle 23-5.77 ± 13.50
Change at Cycle 25-7.28 ± 10.53
Change at Cycle 27-4.94 ± 8.68
Change at Cycle 29-8.80 ± 10.12
Change at Cycle 31-6.69 ± 12.61
Change at Cycle 33-7.90 ± 13.08
Change at Cycle 35-8.88 ± 11.53
Change at EOT-6.67 ± 17.38

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to the final visit (214 weeks) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)48/779 (6.2%)272/779 (34.9%)744/779 (95.5%)
Most frequent serious events
Showing 10 of 175
Most frequent serious events
EventAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
DiarrhoeaGastrointestinal disorders39/779
Disease ProgressionGeneral disorders23/779
NeutropeniaBlood and lymphatic system disorders14/779
Febrile NeutropeniaBlood and lymphatic system disorders12/779
Intestinal ObstructionGastrointestinal disorders12/779
PyrexiaGeneral disorders12/779
HypertensionVascular disorders11/779
VomitingGastrointestinal disorders10/779
StomatitisGastrointestinal disorders9/779
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders9/779
Most frequent other events
Showing 10 of 25
Most frequent other events
EventAflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
DiarrhoeaGastrointestinal disorders464/779
HypertensionVascular disorders369/779
NauseaGastrointestinal disorders337/779
StomatitisGastrointestinal disorders329/779
FatigueGeneral disorders283/779
NeutropeniaBlood and lymphatic system disorders277/779
Decreased AppetiteMetabolism and nutrition disorders206/779
AstheniaGeneral disorders192/779
VomitingGastrointestinal disorders190/779
Weight DecreasedInvestigations171/779

Baseline characteristics

Safety population defined as the participants who signed the informed consent form and received at least part of one dose of study treatment.

Age, Continuous
Age, Continuous(years)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Mean60.3 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Female314
Male465
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
White631
Black or African8
American Asian121
Other19
Body Surface Area (BSA)
Body Surface Area (BSA)(m^2)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Mean1.80 ± 0.23
Systolic Blood Pressure
Systolic Blood Pressure(mmHg)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Mean126.4 ± 13.4
Diastolic Blood Pressure
Diastolic Blood Pressure(mmHg)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Mean76.4 ± 9.0
Any Relevant Medical/Surgical History
Any Relevant Medical/Surgical History(Participants)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Count of participants640
History of Thrombovascular Event and/or Presence of Cardiovascular Risk Factor
History of Thrombovascular Event and/or Presence of Cardiovascular Risk Factor(Participants)Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)
Count of participants424

5 further baseline measures are reported on the registry.

08

Study locations

179 sites
  • Investigational Site Number 840-002
    Muscle Shoals, Alabama 35661, United States
  • Investigational Site Number 840-008
    Corona, California 92879, United States
  • Investigational Site Number 840-007
    Fountain Valley, California 92708, United States
  • Investigational Site Number 840-004
    Riverside, California 92501, United States
  • Investigational Site Number 840-006
    Indianapolis, Indiana 46254, United States
  • Investigational Site Number 840-011
    Metairie, Louisiana 70006, United States
  • Investigational Site Number 840-001
    Rockville, Maryland 20850, United States
  • Investigational Site Number 840-010
    Howell, New Jersey 07731, United States
  • Investigational Site Number 840-012
    Albuquerque, New Mexico 87106, United States
  • Investigational Site Number 840-009
    Farmington, New Mexico 87401, United States
  • Investigational Site Number 840-003
    Lake Success, New York 11042, United States
  • Investigational Site Number 840-005
    Middletown, Ohio 45042, United States
  • Investigational Site Number 056010
    Aalst, 9300, Belgium
  • Investigational Site Number 056015
    Arlon, 6700, Belgium
  • Investigational Site Number 056004
    Bonheiden, 2820, Belgium
  • Investigational Site Number 056001
    Edegem, 2650, Belgium
  • Investigational Site Number 056012
    Gent, 9000, Belgium
  • Investigational Site Number 056009
    Haine-Saint-Paul, 7100, Belgium
  • Investigational Site Number 056003
    Liège, 4000, Belgium
  • Investigational Site Number 056007
    Liège, 4000, Belgium
  • Investigational Site Number 056014
    Loverval, 6280, Belgium
  • Investigational Site Number 056013
    Turnhout, 2300, Belgium
  • Investigational Site Number 056002
    Verviers, 4800, Belgium
  • Investigational Site Number 056011
    Yvoir, 5530, Belgium
  • Investigational Site Number 008
    Brasília, 70390-150, Brazil
  • Investigational Site Number 009
    Curitiba, 80530-010, Brazil
  • Investigational Site Number 012
    Fortaleza, Brazil
  • Investigational Site Number 006
    Passo Fundo, 99010-260, Brazil
  • Investigational Site Number 003
    Porto Alegre, 90470-340, Brazil
  • Investigational Site Number 002
    Rio de Janeiro, 22793-080, Brazil
  • Investigational Site Number 011
    Salvador, 40170-070, Brazil
  • Investigational Site Number 013
    Sao Jose do Rio Preto, 15090-000, Brazil
  • Investigational Site Number 001
    São Paulo, 01246-000, Brazil
  • Investigational Site Number 004
    São Paulo, 01308-050, Brazil
  • Investigational Site Number 005
    São Paulo, 01321-000, Brazil
  • Investigational Site Number 124002
    Calgary, T2N 4N2, Canada
  • Investigational Site Number 124003
    Montreal, H1T 2M4, Canada
  • Investigational Site Number 124005
    Montreal, H2W1S6, Canada
  • Investigational Site Number 124004
    Ottawa, K1H8L6, Canada
  • Investigational Site Number 124006
    Québec, G1S4L8, Canada
  • Investigational Site Number 124001
    Toronto, M4N3M5, Canada
  • Investigational Site Number 152001
    Santiago, Chile
  • Investigational Site Number 152003
    Santiago, Chile
  • Investigational Site Number 203005
    Brno, 65653, Czechia
  • Investigational Site Number 203003
    Olomouc, 77900, Czechia
  • Investigational Site Number 203001
    Ostrava, 70852, Czechia
  • Investigational Site Number 203002
    Praha 2, 12808, Czechia
  • Investigational Site Number 203004
    Praha 5, 15006, Czechia
  • Investigational Site Number 203006
    Zlin, Czechia
  • Investigational Site Number 208001
    Cph Ø, 2100, Denmark
  • Investigational Site Number 208003
    Hillerød, 3400, Denmark
  • Investigational Site Number 208002
    Odense C, 5000, Denmark
  • Investigational Site Number 246001
    Oulu, 90220, Finland
  • Investigational Site Number 246002
    Turku, 20520, Finland
  • Investigational Site Number 276-016
    Aschaffenburg, 63739, Germany
  • Investigational Site Number 276-010
    Augsburg, 86150, Germany
  • Investigational Site Number 276-011
    Berlin, 10707, Germany
  • Investigational Site Number 276-012
    Erlangen, 91054, Germany
  • Investigational Site Number 276-009
    Frankfurt am Main, 60389, Germany
  • Investigational Site Number 276-013
    Frankfurt am Main, 60590, Germany
  • Investigational Site Number 276-004
    Halle, 06120, Germany
  • Investigational Site Number 276-007
    Krefeld, 47805, Germany
  • Investigational Site Number 276-003
    Lebach, 66822, Germany
  • Investigational Site Number 276-019
    Leipzig, 04103, Germany
  • Investigational Site Number 276-008
    Ludwigsburg, 71640, Germany
  • Investigational Site Number 276-018
    Magdeburg, 39104, Germany
  • Investigational Site Number 276-014
    Magdeburg, 39130, Germany
  • Investigational Site Number 276-006
    Moers, 47441, Germany
  • Investigational Site Number 276-001
    München, 81377, Germany
  • Investigational Site Number 276-002
    München, 81737, Germany
  • Investigational Site Number 276-015
    Northeim, 37154, Germany
  • Investigational Site Number 276-017
    Velbert, 42551, Germany
  • Investigational Site Number 276-005
    Weiden/Oberpfalz, 92637, Germany
  • Investigational Site Number 276-020
    Wolfsburg, 38440, Germany
  • Investigational Site Number 372002
    Dublin 24, Ireland
  • Investigational Site Number 372004
    Galway, Ireland
  • Investigational Site Number 372001
    Wilton, Ireland
  • Investigational Site Number 376002
    Haifa, 31096, Israel
  • Investigational Site Number 376001
    Jerusalem, 91120, Israel
  • Investigational Site Number 376005
    Petach Tikva, 49100, Israel
  • Investigational Site Number 376003
    Tel Aviv, 64239, Israel
  • Investigational Site Number 376004
    Tel Hashomer, 52621, Israel
  • Investigational Site Number 380-005
    Ancona, 60100, Italy
  • Investigational Site Number 380-029
    Bergamo, 24128, Italy
  • Investigational Site Number 380-021
    Bologna, 40133, Italy
  • Investigational Site Number 380-004
    Brescia, Italy
  • Investigational Site Number 380-007
    Candiolo, Italy
  • Investigational Site Number 380-012
    Catania, Italy
  • Investigational Site Number 380-019
    Catanzaro, Italy
  • Investigational Site Number 380-023
    Firenze, Italy
  • Investigational Site Number 380-001
    Genova, 16132, Italy
  • Investigational Site Number 380-014
    Meldola, Italy
  • Investigational Site Number 380-016
    Messina, Italy
  • Investigational Site Number 380-013
    Milano, Italy
  • Investigational Site Number 380-015
    Milano, Italy
  • Investigational Site Number 380-025
    Milano, Italy
  • Investigational Site Number 380-022
    Napoli, Italy
  • Investigational Site Number 380-028
    Novara, Italy
  • Investigational Site Number 380-017
    Padova, Italy
  • Investigational Site Number 380-002
    Pisa, Italy

Showing the first 100 of 179 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Riechelmann RP, Srimuninnimit V, Bordonaro R, Kavan P, Di Bartolomeo M, Maiello E, Cicin I, Garcia-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, Karthaus M, Aparicio J, Heinemann V, Picard P, Bury D, Drea E, Sobrero A. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clin Colorectal Cancer. 2019 Sep;18(3):183-191.e3. doi: 10.1016/j.clcc.2019.05.003. Epub 2019 May 15. PubMed 31221542 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Jan 2017, 56 months.

Results were first posted in Feb 2018, 1 year after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 56 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2012
First posted
Apr 5, 2012
StartActual
May 30, 2012
Primary completionActual
Jan 31, 2017
CompletionActual
Jan 31, 2017
Results first posted
Feb 27, 2018
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01571284
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 5, 2012
Start date
May 30, 2012
Primary completion
Jan 31, 2017
Completion
Jan 31, 2017
Results posted
Feb 27, 2018
Last update
Apr 17, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion